SG10202000496XA - Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same - Google Patents

Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same

Info

Publication number
SG10202000496XA
SG10202000496XA SG10202000496XA SG10202000496XA SG10202000496XA SG 10202000496X A SG10202000496X A SG 10202000496XA SG 10202000496X A SG10202000496X A SG 10202000496XA SG 10202000496X A SG10202000496X A SG 10202000496XA SG 10202000496X A SG10202000496X A SG 10202000496XA
Authority
SG
Singapore
Prior art keywords
hepe
methods
same
pharmaceutical compositions
treating asthma
Prior art date
Application number
SG10202000496XA
Other languages
English (en)
Inventor
Mehar Manku
John Climax
Kevin Duffy
Original Assignee
Afimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Afimmune Ltd filed Critical Afimmune Ltd
Publication of SG10202000496XA publication Critical patent/SG10202000496XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SG10202000496XA 2014-01-10 2015-01-12 Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same SG10202000496XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461926052P 2014-01-10 2014-01-10

Publications (1)

Publication Number Publication Date
SG10202000496XA true SG10202000496XA (en) 2020-03-30

Family

ID=53520398

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202000496XA SG10202000496XA (en) 2014-01-10 2015-01-12 Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
SG11201605601UA SG11201605601UA (en) 2014-01-10 2015-01-12 Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201605601UA SG11201605601UA (en) 2014-01-10 2015-01-12 Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same

Country Status (15)

Country Link
US (2) US20150196521A1 (enrdf_load_stackoverflow)
EP (1) EP3091959A4 (enrdf_load_stackoverflow)
JP (2) JP2017505809A (enrdf_load_stackoverflow)
KR (1) KR20160132372A (enrdf_load_stackoverflow)
CN (1) CN106029051A (enrdf_load_stackoverflow)
AU (1) AU2015204531B2 (enrdf_load_stackoverflow)
BR (1) BR112016015997A2 (enrdf_load_stackoverflow)
CA (1) CA2935986A1 (enrdf_load_stackoverflow)
IL (1) IL246623A0 (enrdf_load_stackoverflow)
MX (1) MX2016008953A (enrdf_load_stackoverflow)
PH (1) PH12016501371A1 (enrdf_load_stackoverflow)
RU (2) RU2685706C2 (enrdf_load_stackoverflow)
SG (2) SG10202000496XA (enrdf_load_stackoverflow)
WO (1) WO2015106215A2 (enrdf_load_stackoverflow)
ZA (1) ZA201605492B (enrdf_load_stackoverflow)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013170006A2 (en) 2012-05-10 2013-11-14 Solutex Na Llc Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
ES2727387T3 (es) 2013-11-15 2019-10-15 Ds Biopharma Ltd Sal de lisina de ácido 15-hidroxi-8(Z),11(Z),13(E)-eicosatrienoico
CN107405324A (zh) * 2015-01-16 2017-11-28 艾菲穆恩有限公司 包含15‑hepe的组合物和其使用方法
WO2017013492A1 (en) 2015-07-21 2017-01-26 Dignity Sciences Limited Compositions comprising 15-hepe for use in treating or preventing cancer and neurologic disease
US10653703B2 (en) 2015-09-03 2020-05-19 Solutex Na Llc Compositions comprising omega-3 fatty acids, 17-HDHA and 18-HEPE and methods of using same
KR20180094516A (ko) * 2015-12-18 2018-08-23 애피뮨 리미티드 15-hepe를 포함하는 조성물 및 이를 사용하는 방법
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
CN111481550A (zh) * 2020-05-14 2020-08-04 王兆霖 含有噻托溴铵和阿福特罗的药物制剂

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05186342A (ja) * 1992-01-10 1993-07-27 Fujirebio Inc 免疫調節作用を併せもつ抗炎症剤
ATE504557T1 (de) * 2000-02-16 2011-04-15 Brigham & Womens Hospital Aspirin-ausgelöste lipidmediatoren
US20020188024A1 (en) * 2000-08-23 2002-12-12 Chilton Floyd H. Fatty acid-containing emulsion with increased bioavailability
US20060160095A1 (en) * 2002-12-13 2006-07-20 Eirx Therapeutics Limited Survivin
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
CN101128196B (zh) * 2005-03-16 2013-01-02 Meda制药有限及两合公司 用于治疗呼吸系统疾病的抗胆碱能药和白三烯受体拮抗剂的组合
EP2607358A4 (en) * 2010-08-19 2014-01-29 Univ Tokyo NEW OMEGA-3 FATTY ACIDS RECOVERY-RESISTANT METABOLITE
US10154977B2 (en) * 2011-03-25 2018-12-18 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US8293790B2 (en) * 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
US20120264705A1 (en) * 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) * 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
WO2013170006A2 (en) * 2012-05-10 2013-11-14 Solutex Na Llc Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
MA41120A (fr) * 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci

Also Published As

Publication number Publication date
CN106029051A (zh) 2016-10-12
US20150196521A1 (en) 2015-07-16
WO2015106215A2 (en) 2015-07-16
RU2016132762A3 (enrdf_load_stackoverflow) 2018-09-20
ZA201605492B (en) 2018-11-28
AU2015204531A1 (en) 2016-08-18
RU2016132762A (ru) 2018-02-16
MX2016008953A (es) 2017-02-02
RU2019110980A (ru) 2019-08-26
AU2015204531B2 (en) 2019-11-14
RU2685706C2 (ru) 2019-04-23
BR112016015997A2 (pt) 2018-03-27
IL246623A0 (en) 2016-08-31
WO2015106215A3 (en) 2016-02-18
CA2935986A1 (en) 2015-07-16
KR20160132372A (ko) 2016-11-18
SG11201605601UA (en) 2016-08-30
JP2017505809A (ja) 2017-02-23
US20160324820A1 (en) 2016-11-10
EP3091959A2 (en) 2016-11-16
JP2020002150A (ja) 2020-01-09
EP3091959A4 (en) 2017-09-20
PH12016501371A1 (en) 2016-08-15

Similar Documents

Publication Publication Date Title
ZA201901279B (en) Compositions and methods for treatment of neurological disorders
IL251066B (en) Preparations and methods for the treatment of metabolic disorders
ZA201700311B (en) Compositions and methods of use for treating metabolic disorders
IL250744A0 (en) A method for preparing flavociclib and its pharmaceutical preparations
IL259246A (en) Preparations containing pharmaceutical substances and methods of using them
EP3183005A4 (en) Methods and compositions for the treatment of metabolic disorders
ZA201605492B (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
IL265881A (en) Inhaler and methods of use thereof
GB201411241D0 (en) Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
IL255565A (en) Substituted benzamides and methods of use thereof
GB201410250D0 (en) Improvements to nasal compositions and method of use thereof
GB201404403D0 (en) Compositions and methods relating to the treatment of diseases
IL320533A (en) Methods and compositions for treating disorders and diseases involving RDH12
EP3131556A4 (en) Methods and compositions for treatment of copd diseases
SG11201702554QA (en) Compositions and methods for the treatment of multiple sclerosis
EP3154616A4 (en) Methods and apparatus for treatment of respiratory disorders
GB201408387D0 (en) Treatment of respiratory disorders
ZA201802134B (en) Therapeutic compounds and methods of use thereof
EP3142674A4 (en) Methods and compositions for treatment of macrophage-related disorders
IL259710A (en) Preparations and methods for the treatment of Davidson's disease (microvillus inclusion disease) and related diseases
GB201511799D0 (en) Composition and methods of treatment
IL251736B (en) Methods and compositions for the treatment of radiation-related disorders
PT3233233T (pt) Composições despumantes compreendendo partículas anfifílicas e métodos de preparação e utilização das mesmas
EP3151862A4 (en) Therapeutic detoxification compositions and methods of making and using same
EP3280406A4 (en) COMPOSITIONS AND METHODS FOR TREATING MOVEMENT DISORDERS